RVX-208 a selective bromodomain extra-terminal protein inhibitor reduces mace in patients with high residual risks of cardiovascular disease, a post-hoc analysis. Issue 1 (July 2015) - Wong, N.C.W.; Johansson, J.O.; Lebioda, K.; Halliday, C.; Kulikowski, E.